United Kingdom (UK)
Recombinant monoclonal antibody to HDGF. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma C1.
UniProt Accession Number of Target Protein: P51858
Alternative Name(s) of Target: Hepatoma-derived growth factor; High mobility group protein 1-like 2; HMG-1L2
Immunogen: The original antibody was raised by immunizing mice with full-length recombinant HDGF. This antibody binds a different epitope on HDGF than antibody H3.
Specificity: This antibody is specific for the HDGF protein.
Application Notes: This antibody was used for immunoprecipitation on total cell lysates from H460 NSCLC cells (US20070243191). The neutralizing ability of this antibody was tested on A549. The result was a significant decrease in tumor size (US20070243191). This antibody was fluorescently labelled and injected into nude mice to test the antibody distribution. The antibodies evenly distributed in the animals including the tumors. This antibody entered into both cytoplasm and nuclear mainly in the tumor cells (US20070243191). Immunohistochemistry with this antibody was performed on tissues from NSCLC patients (US20070243191). NSCLC tissue was injected in mice and later harvested. This harvested tumor tissue was then used for immunohistochemistry with this antibody (Zhao et al, 2013; pmid:23695169). Western blot was performed on HDGF protein using this antibody (Ren et al, 2009;pmid:19435872).
Antibody first published in:
Ren et al. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. (2009); 8(5): 1106–1112. PMID:19435872
Note on publication:
Describes the generation of anti-HDGF monoclonal antibodies and reports their anti-tumor activity in lung cancer xenograft models.